Additionally, IGFBP competitively binds to IGF, preventing it from binding to the IGF receptor, and demonstrates anti-metastatic, anti-angiogenic, and anti-tumor activity in NSCLC cells (57). This evidence concerns the gene IGF1 and non-small cell lung carcinoma.